Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells $20,404.80 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Eric Crombez sold 520 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $39.24, for a total transaction of $20,404.80. Following the completion of the sale, the executive vice president now owns 71,530 shares in the company, valued at $2,806,837.20. This represents a 0.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Eric Crombez also recently made the following trade(s):

• On Monday, April 21st, Eric Crombez sold 242 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $35.11, for a total transaction of $8,496.62.

Ultragenyx Pharmaceutical Trading Down 4.7 %

Shares of NASDAQ RARE opened at $33.42 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $29.59 and a 1 year high of $60.37. The firm’s 50-day moving average is $37.18 and its 200-day moving average is $42.74. The firm has a market capitalization of $3.14 billion, a PE ratio of -5.27 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Ultragenyx Pharmaceutical’s revenue was up 28.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.03) earnings per share. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RARE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Wedbush restated a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $92.79.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RARE. Mackenzie Financial Corp boosted its holdings in Ultragenyx Pharmaceutical by 15.8% during the first quarter. Mackenzie Financial Corp now owns 18,658 shares of the biopharmaceutical company’s stock worth $676,000 after buying an additional 2,543 shares during the last quarter. TD Asset Management Inc raised its position in shares of Ultragenyx Pharmaceutical by 48.1% in the 1st quarter. TD Asset Management Inc now owns 138,484 shares of the biopharmaceutical company’s stock valued at $5,015,000 after acquiring an additional 45,000 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $1,178,000. ANTIPODES PARTNERS Ltd acquired a new position in Ultragenyx Pharmaceutical during the first quarter valued at approximately $57,000. Finally, Pier 88 Investment Partners LLC increased its stake in Ultragenyx Pharmaceutical by 58.8% in the first quarter. Pier 88 Investment Partners LLC now owns 22,370 shares of the biopharmaceutical company’s stock valued at $810,000 after purchasing an additional 8,280 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.